Curcumin and Non-alcoholic Fatty Liver Disease (NAFLD) (2)

Suggested Daily Dose of Curcumin C3 Complex

Curcumin has been approved by the U.S. Food and Drug Administration as being GRAS (generally recognized as safe).

Curcumin C3 Complex has nutraceutical applications of antioxidant, anti-inflammatory, anti-carcinogenic, and anti-mutagenic. The recommended dosage of Curcumin C3 Complex by the manufacturer is 200-400 mg in two divided doses daily although 500 mg daily was used in the study.

Suggested Daily Dose of Curcumin C3 Complex

Curcumin has been approved by the U.S. Food and Drug Administration as being GRAS (generally recognized as safe).

Curcumin C3 Complex has nutraceutical applications of antioxidant, anti-inflammatory, anti-carcinogenic, and anti-mutagenic. The recommended dosage of Curcumin C3 Complex by the manufacturer is 200-400 mg in two divided doses daily although 500 mg daily was used in the study.

Possible Mechanisms

NAFLD has been associated with metabolic disorders, and many confounders such as hyperlipidemia, hypertension, obesity, and diabetes.

Studies on epidemiology, risk factors, and markers of inflammation tried to understand the causal role of low-grade inflammation on the development of different metabolic comorbidities such as NAFLD, cardiovascular disease (CVD), diabetes, and metabolic syndrome in obese conditions. Research indicated that abnormal levels of proinflammatory cytokines such as C-reactive protein, tumor-necrosis factor-α, and interleukine-6 play a central role in obesity and are strongly associated with increased risks of metabolic syndrome such as NAFLD. 

Also, researchers found that energy and carbohydrate intake were positively correlated with liver steatosis but not with liver fibrosis. These data suggest that reducing dietary carbohydrates from the diet is beneficial on the long term in patients with NAFLD.(11)

Healthy Dietary Intervention for NAFLD

Introducing lifestyle changes such as dietary intervention and increased physical activity are the first-line treatment and are intended to support not only NAFLD but also associated metabolic diseases such as obesity, insulin resistance, diabetes, and dyslipidemia. 

1   Dietary management focuses on weight reduction of overweight or obese people by decreasing total energy intake. It is recommended to limit the intake of saturated fats and trans fatty acids as well as cholesterol. 

2   Dietary recommendations have been made for omega-3 fatty acids, including alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) to achieve nutrient adequacy and exhibit anti-inflammatory activity. 

3   It is important to increase whole grains intake and the share of vegetable protein (i.e. soy) as well as limit the intake of fat meat, milk, and dairy products. 

4    It is beneficial to eat nuts, despite their high energy value, as a source of alpha-linolenic acid, which could lower LDL cholesterol levels. 

5   Also, a key role is to reduce simple sugars and total exclusion of added sugar in the diet. The rise of NAFLD in developed countries is analogous to the increase of fructose consumption, which high intake is directly indicated as the main cause of the disease. 

6   Selecting foods with high fiber content, low glycemic index, and meals composed with low glycemic load is conducive to weight reduction.

7   An important role in supporting NAFLD treatment is attributed to specific actions of phytochemical, vitamin C, D and E supplementation and some probiotic bacteria, as well as curcumin and cinnamon, which may improve insulin sensitivity. 

8   According to the World Health Organization (WHO), regular physical activity has significant health benefits as the supplement of healthy lifestyle.

Read More：

Curcumin and Non-alcoholic Fatty Liver Disease (NAFLD) (1)

References

(1)  Biochem Pharmacol. 2008;75:787–809.

(2)  Food Chem Toxicol. 2015; 83, 111–124. 

(3)  Br. J. Pharmacol. 2017; 174, 1325–1348.

(4)  Mol. Pharm. 2007; 4, 807–818.

(5)  U.S. PATENT #5,861,415 (1999) and INTERNATIONAL PATENT: European     Patent # EP0839037 (2002)

(6)  J. Hepatol. 2016; Dec; 65(6): 1245–1257.

(7)      The American Liver Foundation: https://liverfoundation.org

(8)  J Hepatol. 2015; Apr;62(1 Suppl):S47-64.

(9)  Hepatology. 2019; Oct;70(4):1119-1133.

(10)      J. Cell Biochem. 2019; Sep;120(9):15989-15996.

(11)      Int. J Endocrinol. 2013; 2013: 428542.

Date: November 18, 2019

Remark:

Author is not affiliated with the maker of Curcumin C3 Complex product.

About the Author:

Lin Zhang, M.D., senior director of a health care industry company in the United States. With the experience in clinical medicine, biotechnology, health industry and other fields, he is responsible for the research and development of plant medicine, functional food and health products. He was a clinician and worked for the National Cancer Institute, FDA and the National Cancer Center of Japan for many years.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of En-CPhI.CN,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.